Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sierra A Colavito

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Oncology|March 10, 2020
AXL as a Target in Breast Cancer TherapySierra A Colavito
Breast Cancer Research : BCR|September 26, 2014
Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathwaySierra A Colavito, Mike R Zou, Qin Yan, et al.
Oncotarget|August 27, 2019
Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancerSierra A Colavito, James T Platt, Matthew A Held, et al.
Nature Genetics|February 11, 2004
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiationKimberly Stegmaier, Kenneth N Ross, Sierra A Colavito, et al.
Molecular Cancer Research : MCR|May 10, 2011
NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53Kathleen A Wilson, Sierra A Colavito, Vincent Schulz, et al.
Journal of Bacteriology|November 4, 2005
Genetic composition of the Bacillus subtilis SOS systemNora Au, Elke Kuester-Schoeck, Veena Mandava, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Oncology|March 10, 2020
AXL as a Target in Breast Cancer TherapySierra A Colavito
Breast Cancer Research : BCR|September 26, 2014
Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathwaySierra A Colavito, Mike R Zou, Qin Yan, et al.
Oncotarget|August 27, 2019
Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancerSierra A Colavito, James T Platt, Matthew A Held, et al.
Nature Genetics|February 11, 2004
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiationKimberly Stegmaier, Kenneth N Ross, Sierra A Colavito, et al.
Molecular Cancer Research : MCR|May 10, 2011
NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53Kathleen A Wilson, Sierra A Colavito, Vincent Schulz, et al.
Journal of Bacteriology|November 4, 2005
Genetic composition of the Bacillus subtilis SOS systemNora Au, Elke Kuester-Schoeck, Veena Mandava, et al.
Pageof 1